Pharmacological Options for Smoking Cessation

Kevin Scott Ferentz, M.D.

Associate Professor
Dept of Family and Community Medicine
University of Maryland School of Medicine

Cigarette smoking is the single most important cause of disease and premature death in the United States

Pharmacological treatment

- NRT "methadone for the smoker"
 - Gum
 - Patch
 - nasal spray
 - Inhaler
 - lozenge
- bupropion
- varenicline
- all decrease cravings, withdrawal
- 20-25% quit rates at 1 year

Nicotine replacement - gum

- available since 1984
- 2 mg. and 4 mg. strength
- "chew, park, chew, park"
- 2 mg. 30 pieces/day maximum
- 4 mg. 20 pieces/day maximum
- wean after 3 months, 6 months maximum
- use in conjunction with patches, bupropion

Nicotine replacement - patches

- 7, 14, 21 mg patches OTC
- 21 mg X 6 wk, 14 mg X 2 wk, 7 mg X 2 wk
- wean vs. single dose
- first patch night before quit day
- rashes, abnormal dreams
- no euphoria no stimulant effect
- no increased risk of MI

Nicotine nasal spray


- one dose: 2 sprays (1 mg)
- minimum: 8 doses/day
- maximum: 40 doses/day (1/2 bottle)
- if not abstinent by week 4 stop
- use for 8 weeks
- Taper over 4-6 weeks
- nasal irritation limits use
- Cost: at least \$ 3/d

Nicotine inhaler

- nicotine deposited in mouth
- 4 mg per insert, 50% absorbed
- 80 puffs in 20 minutes
- 6 16 cartridges/day
- 3 months then wean over 3 months
- 40% throat irritation
- \$ 1 per cartridge

Nicotine lozenges (Commit®)

- 2 and 4 mg strengths
- 4 mg if smoke w/in 30 minutes of waking
- 12 week program:
 - Weeks 1-6: 1 lozenge every 1 to 2 hours
 - Weeks 7-9: 1 lozenge every 2 to 4 hours
 - Weeks 10-12: 1 lozenge every 4 to 8 hours
- at least 9 per day for the first 6 weeks
- hiccups, heartburn, nausea
- no more than 5 in 6 hours, 20 per day
- \$ 0.30 0.50 per lozenge
- Can work when patch, gum failed



Shiffman S, Dresler CM, et al. Arch Intern Med. 2002;162:1267-1276.


Bupropion (Zyban®)

- Probably works by increasing dopamine in nucleus accumbens
- 150 mg qd X 3 days, 150 mg b.i.d. X 4 days, then QUIT
- continue for 7 12 weeks
- if not stopped by 8 weeks, discontinue
- Can use with nicotine replacement

Bupropion - contraindications

- seizure disorder
- prior or current eating disorder
- MAO inhibitors
- concurrent use of Wellbutrin®

Rates of Continuous Abstinence



Jorenby NEJM 1999

- ■Buproption and nicotine patch
- □ Bupropion
- Nicotine patch
- **O**Placebo


Meta-Analysis Smoking Cessation Medications (placebo controlled trials, 6 month quit rates)

Therapy	# studies	Abstinence Rate	Odds ratio (vs. placebo)
Gum	13	23.7	1.5
Patch	27	17.7	1.9
Inhaler	4	22.8	2.5
Nasal spray	3	30.5	2.7
Bupropion SR	2	30.5	2.1

Adapted from Fiore MC U.S. Public Health Service, 2000

Varenicline (Chantix®)

- [alpha]4[beta]2 nicotinic acetylcholine receptors reinforce effects of nicotine, maintain smoking
- partial agonist, antagonist (blocks binding)
- 0.5 mg X 3 d, 0.5 mg b.i.d. X 4 d, 1 mg b.i.d.
- Stop smoking after 7 days on medicine
- Can use for up to 6 months preferable
- Probably higher rates of quitting
- Nausea, constipation, abnormal dreams
- Reports of suicidal ideation, depression
 - No evidence of causal relationship
 - Probably due to cessation of addiction
- Costs about \$ 3-4/day



weeks 9–52: varenicline vs placebo, P<.001; varenicline vs bupropion, P = .004; bupropion vs placebo, P = .08. Jorenby DE, et al JAMA. 296(1):56-63, 2006 Jul 5.

Second-line medications

- Clonidine: 0.15 0.75 mg/d for 3 10 weeks
- Nortriptyline: 75 100 mg/d for 12 weeks

All pharmacotherapy should <u>always</u> be used in conjunction with behavior modification

How are we doing with our patients?

- **1991**:
 - < 50% of patients reported ever being told to stop¹
- **1998**:
 - 67% Ask, 74% Advise, 35% Assist, 8% Follow-up²
- 2003: (patients that got prescription)³
 - 36% told to set quit date, 25% counseled,13% advised to follow up

Many smokers do not get the advice and help they need!!!

¹Frank,E., Winkleby, M.A.,Altman, D.G., et al. *JAMA* 1991;266:3139-3134. ²Goldstein MG, et al. Preventive Medicine. 27(5 Pt 1):720-9, 1998 Sep-Oct. ³Solberg LI, et al. Archives of internal medicine, 2005;165:656

The future

- Nicotine vaccine (NicVAX)
 - Phase two trials are promising
 - five shots in six months
 - antibodies attach to nicotine in bloodstream, prevent crossing blood-brain barrier
 - six months after last shot
 - -14-16% quit rate, 6% w/ placebo
- Different forms of nicotine replacement
- Rimonabant
 - cannabinoid receptor antagonist
 - Also treats obesity
 - Won't be released in US